Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway.
Vivace Therapeutics has raised $35.0M in total funding. The most recent round was Series D. The last funding was announced in March 2025.
Vivace Therapeutics's investors include Sequoia Capital, RA Capital Management, Canaan Partners, Mission BioCapital, Mission Bay Capital.
Vivace Therapeutics is headquartered in San Mateo, United States.
Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway.
Vivace Therapeutics is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vivace Therapeutics — Funding & Investors." VCBacked, March 12, 2025, https://www.vcbacked.co/company/vivace-therapeutics. Accessed July 19, 2026.
VCBacked. (2025). Vivace Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/vivace-therapeutics
{{cite web |title=Vivace Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/vivace-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated